|
|
News Breaks | | | | January 28, 2013 | | 09:00 EDT |  | RPRX | Repros Therapeutics falls 5.7%
Repros Therapeutics is down 5.7%, or $1.06, to $17.55 | |
|
News For RPRX From The Last 14 Days Check below for free stories on RPRX the last two weeks. |
|
|
| June 17, 2013 | | 16:02 EDT |  | RPRX | Repros Therapeutics commences offering of 3M shares of common stock
 Subscribe for More Information | | | 14:21 EDT |  | RPRX | Repros Therapeutics amends PHS patent license agreement
In a regulatory filing, Repros Therapeutics disclosed that on June 14, Repros entered into the Ninth Amendment to the PHS Patent License Agreement dated April 16, 1999, by and between the National Institutes of Health, the Centers for Disease Control or the Food and Drug Administration, collectively, the Public Health Service or PHS, agencies of the United States Public Health Service within the Department of Health and Human Services and the company.The Ninth Amendment substitutes and amends the development benchmarks that the company is required to meet under the Agreement. The company is also filing herewith the Eighth Amendment to the Agreement dated April 20, 2010, which added additional molecules licensed to the Company from PHS under the Agreement. | | | June 12, 2013 | | 11:32 EDT |  | RPRX | Options with decreasing implied volatility: TIVO LAMR FRAN RPRX NAV
| |
|
|
|
|
|
|
